140 related articles for article (PubMed ID: 26299212)
21. Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.
Browne BC; Hochgräfe F; Wu J; Millar EK; Barraclough J; Stone A; McCloy RA; Lee CS; Roberts C; Ali NA; Boulghourjian A; Schmich F; Linding R; Farrow L; Gee JM; Nicholson RI; O'Toole SA; Sutherland RL; Musgrove EA; Butt AJ; Daly RJ
FEBS J; 2013 Nov; 280(21):5237-57. PubMed ID: 23876235
[TBL] [Abstract][Full Text] [Related]
22. Obesity, cholesterol metabolism, and breast cancer pathogenesis.
McDonnell DP; Park S; Goulet MT; Jasper J; Wardell SE; Chang CY; Norris JD; Guyton JR; Nelson ER
Cancer Res; 2014 Sep; 74(18):4976-82. PubMed ID: 25060521
[TBL] [Abstract][Full Text] [Related]
23. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
[TBL] [Abstract][Full Text] [Related]
24. Increased 27-hydroxycholesterol plasma level in men with low high density lipoprotein-cholesterol may circumvent their reduced cell cholesterol efflux rate.
Nunes VS; Panzoldo NB; Leança CC; Parra ES; Zago VS; da Silva EJ; Cazita PM; Nakandakare ER; de Faria EC; Quintão EC
Clin Chim Acta; 2014 Jun; 433():169-73. PubMed ID: 24657483
[TBL] [Abstract][Full Text] [Related]
25. Origin of oxysterols in hepatic bile of patients with biliary infection.
Yoshida T; Matsuzaki Y; Haigh WG; Fukushima S; Ikezawa K; Tanaka N; Lee SP
Am J Gastroenterol; 2003 Oct; 98(10):2275-80. PubMed ID: 14572579
[TBL] [Abstract][Full Text] [Related]
26. MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance.
Atanaskova N; Keshamouni VG; Krueger JS; Schwartz JA; Miller F; Reddy KB
Oncogene; 2002 Jun; 21(25):4000-8. PubMed ID: 12037682
[TBL] [Abstract][Full Text] [Related]
27. 27-Hydroxycholesterol: a potential endogenous regulator of estrogen receptor signaling.
DuSell CD; McDonnell DP
Trends Pharmacol Sci; 2008 Oct; 29(10):510-4. PubMed ID: 18722677
[TBL] [Abstract][Full Text] [Related]
28. 27-Hydroxycholesterol: the first identified endogenous SERM.
Umetani M; Shaul PW
Trends Endocrinol Metab; 2011 Apr; 22(4):130-5. PubMed ID: 21353593
[TBL] [Abstract][Full Text] [Related]
29. A naringenin-tamoxifen combination impairs cell proliferation and survival of MCF-7 breast cancer cells.
Hatkevich T; Ramos J; Santos-Sanchez I; Patel YM
Exp Cell Res; 2014 Oct; 327(2):331-9. PubMed ID: 24881818
[TBL] [Abstract][Full Text] [Related]
30. Long-term pattern of disease recurrence among patients with early-stage breast cancer according to estrogen receptor status and use of adjuvant tamoxifen.
Khoshnoud MR; Fornander T; Johansson H; Rutqvist LE
Breast Cancer Res Treat; 2008 Jan; 107(1):71-8. PubMed ID: 18043896
[TBL] [Abstract][Full Text] [Related]
31. Mechanisms of FGFR3 actions in endocrine resistant breast cancer.
Tomlinson DC; Knowles MA; Speirs V
Int J Cancer; 2012 Jun; 130(12):2857-66. PubMed ID: 21792889
[TBL] [Abstract][Full Text] [Related]
32. Tamoxifen inhibits ER-negative breast cancer cell invasion and metastasis by accelerating Twist1 degradation.
Ma G; He J; Yu Y; Xu Y; Yu X; Martinez J; Lonard DM; Xu J
Int J Biol Sci; 2015; 11(5):618-28. PubMed ID: 25892968
[TBL] [Abstract][Full Text] [Related]
33. EphA2 overexpression decreases estrogen dependence and tamoxifen sensitivity.
Lu M; Miller KD; Gokmen-Polar Y; Jeng MH; Kinch MS
Cancer Res; 2003 Jun; 63(12):3425-9. PubMed ID: 12810680
[TBL] [Abstract][Full Text] [Related]
34. Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis.
Johnston SR; Boeddinghaus IM; Riddler S; Haynes BP; Hardcastle IR; Rowlands M; Grimshaw R; Jarman M; Dowsett M
Cancer Res; 1999 Aug; 59(15):3646-51. PubMed ID: 10446976
[TBL] [Abstract][Full Text] [Related]
35. Tamoxifen stimulates the growth of cyclin D1-overexpressing breast cancer cells by promoting the activation of signal transducer and activator of transcription 3.
Ishii Y; Waxman S; Germain D
Cancer Res; 2008 Feb; 68(3):852-60. PubMed ID: 18245487
[TBL] [Abstract][Full Text] [Related]
36. New approaches to reverse resistance to hormonal therapy in human breast cancer.
Weinberg OK; Marquez-Garban DC; Pietras RJ
Drug Resist Updat; 2005 Aug; 8(4):219-33. PubMed ID: 16054421
[TBL] [Abstract][Full Text] [Related]
37. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
Henriksen KL; Rasmussen BB; Lykkesfeldt AE; Møller S; Ejlertsen B; Mouridsen HT
Acta Oncol; 2009; 48(4):522-31. PubMed ID: 19173092
[TBL] [Abstract][Full Text] [Related]
38. Growth inhibition of estrogen receptor-positive and aromatase-positive human breast cancer cells in monolayer and spheroid cultures by letrozole, anastrozole, and tamoxifen.
Kijima I; Itoh T; Chen S
J Steroid Biochem Mol Biol; 2005 Dec; 97(4):360-8. PubMed ID: 16263272
[TBL] [Abstract][Full Text] [Related]
39. The nature of tamoxifen action in the control of female breast cancer.
Kodama M; Kodama T
In Vivo; 2001; 15(4):319-25. PubMed ID: 11695224
[TBL] [Abstract][Full Text] [Related]
40. Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells.
Chang SB; Miron P; Miron A; Iglehart JD
J Surg Res; 2007 Mar; 138(1):37-44. PubMed ID: 17109887
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
